Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mistral Pharma has reported positive results from a first pilot pharmacokinetic study on MIST-B04, a controlled-delivery branded product in the rheumatology and inflammation field.
Subscribe to our email newsletter
The results of this pilot study show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation presently on the market.
MIST-B04 is formulated using a new drug delivery platform named Trizero, which was developed internally by Mistral’s scientists and for which a patent application was filed in June 2007.
Bertrand Bolduc, president & CEO of Mistral Pharma, said: “The results show that our brand new Trizero platform is performing very well in vivo and this opens up many other opportunities for line-extension products for MIST-B04.”